The global antidepressant and Anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 213-page report you will receive 73 tables and 92 figures– all unavailable elsewhere.
The 213-page report provides clear detailed insight into the global antidepressant and anti-anxiety drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global antidepressant and anti-anxiety drugs market forecasts from 2019-2029
• Our investigation shows forecasts to 2029 for the following submarket by drug class:
• Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
• Atypical Antipsychotics
• Tricyclic Antidepressants (TCAs)
• Serotonin Antagonist and Reuptake Inhibitors (SARIs)
• Benzodiazepines
• Monoamine Oxidase Inhibitors (MAOIs)
• Others
• Our investigation shows forecasts to 2029 for the following submarket by indication:
• Major Depressive Disorder (MDD)
• General Anxiety Disorder (GAD)
• Panic Disorder (PD)
• Obsessive Compulsive Disorder (OCD)
• Others
• Our investigation shows forecasts to 2029 for the selected leading drugs:
• Abilify
• Abilify Maintena
• Brintellix/Trintellix
• Cipralex/Lexapro
• Cymbalta
• Invega Sustenna/ Xeplion/Trinza/Trevicta
• Lamictal
• Rexulti
• Risperdal Consta
• Zyprexa
• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: the US, Canada
• Europe: the UK, Germany, Spain, France, Italy, Russia, Rest of Europe
• Asia-Pacific: Japan, China, India, South Korea, Rest of Asia-Pacific
• RoW: Brazil, Mexico, Russia, South Africa, Rest of RoW
• This report also provides discussion and qualitative analysis on:
• Factors that drive and restrain the global antidepressant and Anti-anxiety drugs market.
• Antidepressant drugs pipeline analysis
• Anti-anxiety drugs pipeline analysis
• This report discusses the selected leading companies:
• Allergan plc.
• AstraZeneca plc.
• Eli Lilly and Company
• GlaxoSmithKline plc.
• H. Lundbeck A/S
• Johnson & Johnson
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Ltd.
• Valeant Pharmaceuticals
• Key Questions Answered:
• This report provides in-depth analysis of the antidepressant and anti-anxiety drugs market, identifying the latest trends and forecasting its growth and development over the coming 10 years.
• The study addresses scope of the market in 2018 and assesses commercial drivers and restraints.
• Through reading this report you will gain revenue forecasts from 2018 to 2029 for the overall world market and its leading submarkets, as well as regional and national markets.
• This report provides revenue forecast for the leading antidepressant and anti-anxiety drugs from 2018 to 2019
• Identify drug development trends that will affect market participants from 2018 to 2029.
• See discussions of companies developing, manufacturing, and marketing antidepressant and ant-anxiety drugs, exploring products, technologies, R&D, partnerships, M&A and outlooks.
Visiongain’s study is intended for anyone requiring commercial analyses for the antidepressant and anti-anxiety drugs market. You find data, trends and predictions.
Buy our report today: Global Antidepressant and Anti-anxiety Drugs Market 2019-2029: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Atypical Antipsychotics, Tricyclic Antidepressants (TCAs), Serotonin Antagonist and Reuptake Inhibitors (SARIs), Benzodiazepines; Monoamine Oxidase Inhibitors (MAOIs), Major Depressive Disorder (MDD), General Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive Compulsive Disorder (OCD), Others.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Antidepressant and Anti-anxiety Drugs
2.1 Types of Depression and Anxiety Diseases
2.2 Prevalence and Mortality Profiles for Depression and Anxiety Diseases
2.3 Depression Contributing Factors and Prevention
2.4. History of Antidepressant and Anti-anxiety Drugs Development
2.5 Leading Classes of Antidepressant and Anti-anxiety Drugs
2.5.1 Selective serotonin reuptake inhibitors (SSRIs)
2.5.2 Serotonin-norepinephrine reuptake inhibitors (SNRIs)
2.5.3 Atypical Antipsychotics
2.5.4 Tricyclic antidepressants (TCAs)
2.5.5 Serotonin antagonist and reuptake inhibitors (SARIs)
2.5.6 Benzodiazepines
2.5.7 Monoamine Oxidase Inhibitors (MAOIs)
2.5.8 Other
3. Antidepressant and Anti-anxiety Drugs: World Market 2018-2029
3.1 Global Antidepressant and Anti-anxiety Drugs Revenues Plateau between 2014 and 2017
3.2 Antidepressant and Anti-anxiety Drugs - Market Segmentation
4. Antidepressant and Anti-anxiety Drugs Market by Drug Class 2018-2029
4.1 Selective serotonin reuptake inhibitors (SSRIs)
4.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
4.3 Atypical Antipsychotics
4.4 Tricyclic antidepressants (TCAs)
4.5 Serotonin Antagonist and Reuptake Inhibitors (SARIs)
4.6 Benzodiazepines
4.7 Monoamine Oxidase Inhibitors (MAOIs)
4.8 Other
5. Antidepressant and Anti-anxiety Drugs Market by Indication 2018-2029
5.1 Major Depressive Disorder (MDD)
5.2 Generalized Anxiety Disorder (GAD)
5.3 Panic Disorder (PD)
5.4 Obsessive Compulsive Disorder (OCD)
5.5 Others
6. Antidepressant and Anti-anxiety Drugs Market by Drug Type 2018-2029
6.1 Invega Sustenna/Xeplion/Trinza/Trevicta
6.2 LAMICTAL
6.3 RISPERDAL CONSTA
6.4 Cymbalta
6.5 ABILIFY MAINTENA
6.6 ABILIFY
6.7 Zyprexa
6.8 Rexulti
6.9 Brintellix/Trintellix
6.10 Cipralex/Lexapro
7. Drivers and Restraints in the Antidepressant and Anti-anxiety Drugs Market, 2018-2029
7.1. Market Drivers Analysis
7.1.1 Increasing Geriatric Population
7.1.2 Launch of New Drugs is Expected to Drive the Market Growth
7.1.3 Development of Advanced Antidepressant and Antianxiety Drugs
7.1.4 Increasing Prevalence of Depression and Anxiety
7.1.5 Escalating Mental Healthcare Awareness
7.2 Market Restraints Analysis
7.2.1 Social Stigma of Depression and Anxiety Diseases
7.2.2 Increase in Generic Competition
7.2.3 Stringent Regulatory Guidelines for New Drug Approval
8. Pipeline for Ant-depression and Anti-anxiety Drugs Market, 2018-2029
8.1 Antidepressant Drugs Pipeline Analysis
8.1.1 Esketamine
8.1.2 Rapastinel (GLYX-13)
8.1.3 SAGE-547
8.1.4 ALKS 5461
8.2 Anti-anxiety Drugs Pipeline Analysis
8.2.1 Aloradine (PH94B)
8.2.2 Tonmya (Cyclobenzaprine)
8.2.3 AVN-101
8.2.4 FKW00GA
8.2.5 JNJ-42165279
8.2.6 SRX246
8.2.7 Travivo (Gepirone ER)
8.2.8 Rexulti (Brexpiprazole)
8.2.9 NBTX-001 (Xenon)
9. The Leading National Markets 2018-2029
9.1 US and Europe Dominates the Global Antidepressant and Anti-anxiety Drugs Market
9.2 Above-Average Growth in Emerging Markets: Regional Forecasts 2018-2029
9.3 North America Antidepressant and Anti-anxiety Drugs Market
9.3.1 The US: Leading Market for Antidepressant and Anti-anxiety Drugs
9.3.1.1 The Antidepressant and Anti-anxiety Drugs Market in the U.S.
9.3.1.2 Continued Dominance of the U.S. Market
9.3.2 Canada Market Will Grow at High CAGR in North America Region
9.4 The European Union Forms Second Largest Regional Market
9.4.1 Increasing Prevalence of Chronic Diseases
9.4.2 EU5: Ageing Populations to Drive Market Growth
9.4.3 Germany is Leading the EU Antidepressant and Anti-anxiety Drugs Market
9.4.4 UK Market is Propelled by the Government Initiatives for Mental Health
9.4.5 France Antidepressant and Anti-anxiety Drugs is Projected to Grow at Lucrative CAGR
9.4.6 Italy is Expected Showcase Positive Growth
9.4.7 Spain Market is Projected to Grow at a Lucrative rate During 2018 - 2029
9.5 Asia-Pacific Antidepressant and Anti-anxiety Drugs is Fastest Growing Market
9.5.1 Japan – Still the Second Largest National Market
9.5.1.1 Is the government of Japan doing enough to raise awareness and to prevent suicide?
9.5.2 Chinese Antidepressant and Anti-anxiety Drugs Market
9.5.2.1 China’s Response: Major Efforts Over the Last Decade
9.5.3 Indian Market to Expand by Double Growth Over the Forecast Period
9.5.4 South Korean Market
9.6 RoW Nation Sales Still Expanding – Market Forecast 2018-2029
9.6.1 Brazilian Antidepressant and Anti-anxiety Drugs Market to Double in Size
9.6.2 Mexico Antidepressant and Anti-anxiety Drugs Sales - Forecast 2018-2029
9.6.3 Russia Antidepressant and Anti-anxiety Drugs
9.6.4 South Africa Antidepressant and Anti-anxiety Drugs
10. Leading Companies in the Antidepressant and Antianxiety Drugs Market
10.1 Johnson & Johnson
10.1.1 Business Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Recent Developments (2014-2017)
10.1.5 SWOT Analysis
10.2. Pfizer Inc.
10.2.1 Business Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.5 SWOT Analysis
10.3. AstraZeneca
10.3.1 Business Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Recent Developments
10.3.5 SWOT Analysis
10.4. Otsuka Pharmaceuticals
10.4.1 Business Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Recent Developments (2014-2018)
10.4.5 SWOT Analysis
10.5. Eli Lilly & Co.
10.5.1 Business Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Recent Developments 2018
10.5.5 SWOT Analysis
10.6. GlaxoSmithKline plc
10.6.1 Business Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Recent Developments 2018
10.6.5 SWOT Analysis
10.7 H. Lundbeck A/S
10.7.1 Business Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Recent Developments (2014-2018)
10.7.5 SWOT Analysis
10.8. Allergan plc
10.8.1 Business Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Recent Developments (2014-2018)
10.8.5 SWOT Analysis
10.9. Takeda Pharmaceutical Company Limited
10.9.1 Business Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Recent Developments (2014-2018)
10.9.5 SWOT Analysis
10.10. Bausch Health (Valeant Pharmaceuticals International)
10.10.1 Business Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Recent Developments
10.10.5 SWOT Analysis
11. Qualitative Analysis of the Antidepressant and Anti-anxiety Drugs Industry and Market, 2018
11.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats
11.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antidepressant and Anti-anxiety Drugs Market
11.2.1 Social Factors
11.2.2 Technological Developments
11.2.3 Economic Pressures
11.2.4 Political Issues
12. Antidepressant and Anti-anxiety Drugs Market –2018-2029: Conclusions
12.1 Blockbuster Antidepressant and Anti-anxiety Drugs in 2018 - Leading Brands
12.2 The Leading Drug Class of Antidepressant and Anti-anxiety Drugs in 2018 and 2029
12.3 Antidepressant and Anti-anxiety Drugs – Regional Market Changes
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1 Common Depression and Anxiety Diseases and Their Causes
Table 3.1 Antidepressant and Anti-anxiety Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2014-2017
Table 4.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Size ($bn) and Share (%), 2018
Table 4.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 5.1 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Size ($bn) and Share (%), 2018
Table 5.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 6.1 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Size ($bn) and Share (%), 2018
Table 6.2 Global Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 8.1 Pipeline of Antidepressant Drugs – Phase III, 2017
Table 8.2 Pipeline of Antidepressant Drugs – Phase II, 2017
Table 8.3 Pipeline of Antidepressant Drugs – Phase II, 2017
Table 8.4 Pipeline of Antidepressant Drugs – Phase I, 2017
Table 8.5 Pipeline of Leading Anti-anxiety Drugs, 2017
Table 9.1 Antidepressant and Anti-anxiety Drugs Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2018
Table 9.2 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.3 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.4 North America Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.5 U.S. Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.6 Canada Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.7 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.8 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.9 Europe Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.10 Germany Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.11 UK Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.12 France Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.13 Italy Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.14 Spain Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.15 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.16 Asia-Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.17 Asia Pacific Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.18 Japan Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.19 China Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.20 Indian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.21 South Korea Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.22 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Country ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.23 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Drug Class ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.24 Rest of the World Antidepressant and Anti-anxiety Drugs Market: Revenue Forecasts by Indication ($bn), Annual Growth (%) and CAGR, 2018-2029
Table 9.25 Brazilian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.26 Mexico Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.27 Russia Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 9.28 South Africa Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2018-2029
Table 10.1 Johnson & Johnson: Overview
Table 10.2 Johnson & Johnson: Product Portfolio
Table 10.3 Johnson & Johnson: Recent Developments
Table 10.4 Johnson & Johnson: Merger & Acquisition
Table 10.5 Pfizer Inc.: Overview
Table 10.6 Pfizer Inc.: Product Portfolio
Table 10.7 AstraZeneca: Overview
Table 10.8 AstraZeneca: Product Portfolio
Table 10.9 AstraZeneca: Recent Developments
Table 10.10 Otsuka: Overview
Table 10.11 Otsuka: Product Portfolio
Table 10.12 Otsuka: Recent Developments
Table 10.13 Lilly: Overview
Table 10.14 Lilly: Product Portfolio
Table 10.15 Lilly: Recent Developments
Table 10.16 GlaxoSmithKline: Overview
Table 10.17 GlaxoSmithKline: Product Portfolio
Table 10.18 GlaxoSmithKline: Recent Developments
Table 10.19 H. Lundbeck: Overview
Table 10.20 H. Lundbeck: Product Portfolio
Table 10.21 H. Lundbeck: Recent Developments
Table 10.22 H. Lundbeck: Strategic Collaboration
Table 10.23 Allergan: Overview
Table 10.24 Allergan: Product Portfolio
Table 10.25 Allergan: Recent Developments
Table 10.26 Takeda Pharmaceutical: Overview
Table 10.27 Takeda Pharmaceutical: Product Portfolio
Table 10.28 Takeda Pharmaceutical: Recent Developments
Table 10.27 Bausch Health: Recent Developments
Table 10.28 Bausch Health: Product Portfolio
Table 10.29 Bausch Health: Recent Developments
Table 11.1 Social, Technological, Economic, and Political Factors Affecting the Antidepressant and Anti-anxiety Drugs Market, 2018-2029
List of Figures
Figure 2.1 Cases of Depressive Disorder (in millions) by Region, 2015
Figure 2.2 Cases of Anxiety Disorder (in millions) by Region, 2015
Figure 3.1 Antidepressant and Anti-anxiety Drugs Historic Global Market Size ($bn), 2014-2017
Figure 3.2 Global Antidepressant and Anti-anxiety Drugs Market: Estimates and Forecasts Revenues ($bn), 2018-2029
Figure 4.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Drug Class
Figure 4.2 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2018
Figure 4.3 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2023
Figure 4.4 Global Antidepressant and Anti-anxiety Drugs Market by Drug Class: Market Share (%), 2029
Figure 4.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues ($bn), 2018-2029
Figure 4.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues Share (%), 2018-2029
Figure 4.7 Global SSRIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.8 Global SNRIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.9 Global Atypical Antipsychotics Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.10 Global TCAs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.11 Global SARIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.12 Global Benzodiazepines Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.13 Global MAOIs Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 4.14 Global Other Drug Classes Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 5.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Indication
Figure 5.2 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2018
Figure 5.3 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2023
Figure 5.4 Global Antidepressant and Anti-anxiety Drugs Market by Indication: Market Share (%), 2029
Figure 5.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Indication Revenues ($bn), 2018-2029
Figure 5.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Indication Revenues Share (%), 2018-2029
Figure 5.7 Global MDD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 5.8 Global GAD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 5.9 Global PD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 5.10 Global OCD Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 5.11 Global Other Indications Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.1 Antidepressant and Anti-anxiety Drugs Market: Segment by Drug Type
Figure 6.2 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2018
Figure 6.3 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2023
Figure 6.4 Global Antidepressant and Anti-anxiety Drugs Market by Drug: Market Share (%), 2029
Figure 6.5 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Revenues ($bn), 2018-2029
Figure 6.6 Global Antidepressant and Anti-anxiety Drugs Market: Forecast by Drug Class Revenues Share (%), 2018-2029
Figure 6.7 Global Invega Sustenna/Xeplion/Trinza/Trevicta Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.8 Global LAMICTAL Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.9 Global RISPERDAL CONSTA Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.10 Global Cymbalta Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.11 Global ABILIFY MAINTENA Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.12 Global ABILIFY Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.13 Global Zyprexa Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.14 Global Rexulti Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.15 Global Brintellix /Trintellix Market: Estimates and Forecasts Revenues ($bn), AGR (%), 2018-2029
Figure 6.16 Global Cipralex/Lexapro Market: Estimates and Forecasts Revenues ($bn), 2018-2029
Figure 7.1 Antidepressant and Anti-anxiety Drugs Market: Drivers and Restraints, 2018-2029
Figure 9.1 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2018
Figure 9.2 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2023
Figure 9.3 Antidepressant and Anti-anxiety Drugs Sales by National Markets: Market Share (%), 2029
Figure 9.4 U.S. Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), 2018-2029
Figure 9.5 Canada Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), 2018-2029
Figure 9.6 EU Antidepressant and Anti-anxiety Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2018-2029
Figure 9.7 EU Antidepressant and Anti-anxiety Drugs Market by Leading Country (EU5): Revenue Share Forecasts (%), 2018-2029
Figure 9.8 Germany Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.9 UK Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.10 France Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.11 Italy Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.12 Spain Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.13 Japan Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Growth Rate (%) 2018-2029
Figure 9.14 China Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.15 Indian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.16 South Korea Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.17 Antidepressant and Anti-anxiety Drugs Market in RoW: National Revenue Forecasts ($bn), 2018-2029
Figure 9.18 Antidepressant and Anti-anxiety Drugs Market in RoW: National Revenue Share Forecasts (%), 2018-2029
Figure 9.19 Brazilian Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.20 Mexico Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.21 Russia Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 9.22 South Africa Antidepressant and Anti-anxiety Drugs Market: Revenue Forecast ($bn), Annual Growth (%), 2018-2029
Figure 10.1 Johnson & Johnson: Financial Overview 2014-2017
Figure 10.2 Johnson & Johnson: SWOT Analysis
Figure 10.3 Pfizer Inc.: Financial Overview 2014-2017
Figure 10.4 Pfizer Inc.: SWOT Analysis
Figure 10.5 AstraZeneca: Financial Overview 2014-2017
Figure 10.6 AstraZeneca: SWOT Analysis
Figure 10.7 Otsuka: Financial Overview 2014-2017
Figure 10.8 Otsuka: SWOT Analysis
Figure 10.9 Eli Lilly: Financial Overview 2014-2017
Figure 10.10 Eli Lilly: SWOT Analysis
Figure 10.11 GlaxoSmithKline: Financial Overview 2014-2017
Figure 10.12 GlaxoSmithKline: SWOT Analysis
Figure 10.13 H. Lundbeck: Financial Overview 2014-2017
Figure 10.14 H. Lundbeck: SWOT Analysis
Figure 10.15 Allergan: Financial Overview 2014-2017
Figure 10.16 Allergan: SWOT Analysis
Figure 10.17 Takeda Pharmaceutical: Financial Overview 2014-2017
Figure 10.18 Takeda Pharmaceutical: SWOT Analysis
Figure 10.19 Bausch Health: Financial Overview 2014-2017
Figure 10.20 Bausch Health: SWOT Analysis
Figure 11.1 Strengths and Weaknesses of the Antidepressant and Anti-anxiety Drugs Market, 2018-2029
Figure 11.2 Opportunities and Threats for The Antidepressant and Anti-anxiety Drugs Market, 2018-2029
Figure 12.1 Antidepressant and Anti-anxiety Drugs Market Forecasts: Regional Market Sizes ($bn), 2018-2029
Figure 12.2 Antidepressant and Anti-anxiety Drugs Market Forecasts: Regional Market Share (%), 2018-2029
ACADIA Pharmaceuticals
Actelion, Ltd.
Alkermes
Alkermes Pharma Ireland Ltd.
Allergan plc.
Aptinyx
AstraZeneca plc.
Avineuro Pharmaceuticals
Axsome Therapeutics
Azevan Pharmaceuticals
Bausch Health
BioLite
BlackThorn Therapeutics
Bristol - Myers Squibb (BMS)
Cerecor
Denovo Biopharma
Eli Lilly and Company
Fabre-Kramer Pharmaceuticals
Forest Laboratories
GlaxoSmithKline plc.
H. Lundbeck A/S
Intra-Cellular Therapies
Janssen Pharmaceutica NV
Janssen Pharmaceuticals, Inc.
Janssen Research & Development
Johnson & Johnson (Janssen)
Lupin Pharmaceuticals
Luye Pharma (USA) Ltd.
Luye Pharma Group Ltd
Marinus Pharmaceuticals
Medtronic
Minerva Neurosciences
MSI Methylation Sciences
Neuralstem Inc.
Nobilis Therapeutics
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Pherin Pharmaceuticals
Proteus Digital Health
Reviva Pharmaceuticals
Sage Therapeutics
Sandong Luye Pharmaceutical Co., Ltd.
Sunovion Pharmaceuticals
Supernus Pharmaceuticals
Suven Life Sciences
Taisho Pharmaceutical
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceuticals USA, Inc
Tonix Pharmaceuticals
Valeant Pharmaceuticals
VistaGen Therapeutics
List of Organizations Mentioned in the Report
Anxiety and Depression Association of America (ADAA)
Centers for Disease Control and Prevention (CDC)
European Medicines Agency (EMA)
European Union
Mental Health America
National Mental Health Institute (NIMH)
Organization for Economic Cooperation and Development (OECD)
The American Psychiatric Association (APA)
U.S. National Mental Health Institute
UK National Institute of Health and Clinical Excellence (NICE)
World Economic Forum (WEF)
World Health Organization (WHO)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
